Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
Active, not recruiting · Phase 2 · NCT04917042
Conditions: Peripheral Nerve Sheath Tumor
At a glance
- Research payments reported, 2025
- $83,100
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- University of Florida (with Epizyme, Inc.)
- Tested
- Tazemetostat (drug)
- Dates
- Started 2021-08-25; completion 2026-12
- Results posted
- Yes
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $83,100 in research payments for this study in 2025 (1 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Florida Pediatric $83,100
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.